Retatrutide (“Reta”)
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon pathways. It is being studied for obesity and metabolic conditions but, as of this site’s publication, is not FDA-approved for routine patient use.
Being studied for
Weight management and metabolic health under controlled clinical research.
